Vimarsana
Biggest News Aggregation in the World

Page 4 - Specific Populations News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Specific Populations. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Specific Populations Today - Breaking & Trending Today

"They Don't Treat Us like Human Beings" : Abuse of Imprisoned Women in Japan - Vimarsana News

"They Don't Treat Us like Human Beings" : Abuse of Imprisoned Women in Japan

The 76-page report, “‘They Don’t Treat Us like Human Beings’: Abuse of Imprisoned Women in Japan,” documents the abusive conditions in many women’s prisons in Japan. Government policies towards women in prison violate international human rights conventions and contravene international standards such as the United Nations Standard Minimum Rules of the Treatment of Prisoners, known as the Mandela Rules. Prison authorities use restraints on imprisoned pregnant women, arbitrarily employ solitary confinement as a form of punishment, verbally abuse women in prison, deny incarcerated wome...

Source: hrw.org
2023-11-12 | NDAQ:LXRX | Press Release | Lexicon Pharmaceuticals Inc - Vimarsana News

2023-11-12 | NDAQ:LXRX | Press Release | Lexicon Pharmaceuticals Inc

(2023-11-12 | NDAQ:LXRX) INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data

INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data - Vimarsana News

INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data

Oral presentation delivered at the American Heart Association (AHA) Scientific Sessions 2023 Analysis of clinical data shows statistically significant risk reductions in heart failure and separately in MACE related outcomes as early as approximately three months in patients at high risk for cardiovascular events INPEFA® (sotagliflozin) recently approved by FDA for treatment of heart failure THE WOODLANDS, Texas, Nov. 12, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today

Source: yahoo.com
INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data - Vimarsana News

INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data

Oral presentation delivered at the American Heart Association Scientific Sessions 2023 Analysis of clinical data shows statistically significant risk reductions in heart failure and separately in...

INPEFA® (Sotagliflozin) Receives Coverage From Express Scripts on Its Basic and High Performance Formularies for Commercially Insured Patients - Vimarsana News

INPEFA® (Sotagliflozin) Receives Coverage From Express Scripts on Its Basic and High Performance Formularies for Commercially Insured Patients

As previously reported, Express Scripts has also determined that it will list INPEFA as a preferred product on Medicare national formularies starting today, November 1, 2023 INPEFA recently approved...